Recruiting

Observational Study

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT01577251

Conditions

Neoplasia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this study is to establish a registry and biosample repository (defined as blood, urine, and tumor specimens) in patients with a cancer and/or benign tumor diagnosis undergoing radiotherapy.

Conditions

Neoplasia

Study ID

NCT01577251

Start date

Jun, 2008

Status verified date

Mar, 2026

Completion date

Dec, 2030

Anticipated

Primary completion date

Dec, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

  • Anyone age 18 and above with a cancer and/or benign tumor diagnosis undergoing radiotherapy
  • Able to sign consent

Study Design

Enrollment

8000 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Health Assessments [ Time Frame: 10 years ]

Central Contacts and Locations

Central contacts

Project Manager

radonccru@pennmedicine.upenn.edu

Locations

Virtua Health & Wellness Center

Recruiting

Voorhees Township, New Jersey, United States, 08043

Contacts

Susan VanLoon, RN, ODS-C, CCRP

856-247-7382svanloon@virtua.org

Principal Investigator:

Catherine Kim, MD

Lancaster General Hospital

Recruiting

Lancaster, Pennsylvania, United States, 17604

Contacts

Alyson Eckert, RN

717-544-0511Alyson.Eckert@pennmedicine.upenn.edu

Principal Investigator:

Pamela Boimel, MD, PhD

University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Project Manager

radonccru@pennmedicine.upenn.edu

Principal Investigator:

Jay Dorsey, MD, PhD

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Mar 4, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2026-03-04.